H1 20191 Financial Information and Corporate Business Update
H1 20191 Financial Information and Corporate Business Update
July 30, 2019
Daix (France), July 30, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today reported its cash position as at June 30, 2019 and revenues for the first half of 2019, and provided a corporate business update.
Key financial results
As at June 30, 2019, Inventiva’s cash and cash equivalents were €37.1 million, vs. €56.7 million on December 31, 2018, in line with Company expectations. Net cash flow related to operating activities amounted to -€19.6 million in the first half of 2019 (vs. -€15.3 million in the first half of 2018). R&D expenses for the semester, mainly driven by lanifibranor and odiparcil programs, were up 21.8% compared to the first half of 2018.
Revenues for the first half of 2019 amounted to €1.2 million, compared to €1.4 million in the first half of 2018.
Key highlights of the second quarter
Lanifibranor for the treatment of non-alcoholic steatohepatitis (“NASH”)
In May, the U.S. Food and Drug Administration (FDA) lifted for lanifibranor the clinical hold in place on the peroxisome proliferator-activated receptor (PPAR) target class. This decision enables Inventiva to conduct clinical trials equal to or longer than six months evaluating lanifibranor for the treatment of NASH. It followed the review of the two-year carcinogenicity studies by the FDA’s Executive Carcinogenicity Assessment Committee (ECAC). This decision confirms lanifibranor’s benign safety profile and represents a key milestone for Inventiva as it removes a key obstacle that had prevented the Company from initiating long-term Phase III clinical trials necessary to obtain marketing approval with lanifibranor for the treatment of NASH.
1 Financial information not audited in accordance with IFRS standards.
PRESS RELEASE
The NATIVE (NASH Trial To Validate IVA337 Efficacy) Phase IIb clinical study is progressing as planned and, at the end of June, 211 patients out of a target of 225 had been randomized in the study. The results will be published, as expected, in the first half of 2020.
Odiparcil for the treatment of mucopolysaccharidoses (“MPS”)
Early June, Inventiva announced the completion of patient recruitment in its iMProveS (improve MPS treatment) Phase IIa clinical study in Europe evaluating odiparcil for the treatment of mucopolysaccharidosis type VI (MPS VI).
The patients participating in the trial are distributed among the various arms, with fifteen patients being treated with enzyme replacement therapy (ERT) and receiving one of the two doses of odiparcil or placebo and five patients not being treated with ERT and only receiving the high dose of odiparcil. The headline results of the fifteen ERT-treated patients are expected by the end of the year. The results of the five patients not being treated with ERT are expected during the first quarter of 2020.
YAP-TEAD in the field of oncology
In May, Inventiva presented new reslts from its YAP-TEAD oncology program at the AACR Special Conference on The Hippo Pathway: Signaling, Cancer, and Beyond. These results showed that Inventiva’s YAP-TEAD inhibitors significantly reduced tumor growth in Malignant Pleural Mesothelioma (MPM) xenograft and orthotopic models. In addition, synergistic effects were seen in a three-dimensional spheroid model suggesting that Inventiva’s YAP-TEAD inhibitors, when used in combination with existing chemotherapeutics, could attenuate multidrug resistance and re-sensitize chemo-resistant cancer cells.
Following these promising results, Inventiva has decided to expand its research to other cancer indications as well as other combination strategies where standard of care agents are proven to be ineffective and where YAP is activated.
ABBV-157 for the treatment of moderate to severe psoriasis
AbbVie has initiated a new clinical study with ABBV-157, the drug candidate resulting from its collaboration with Inventiva, aiming at assessing the compound’s pharmacokinetics, safety and tolerance in healthy volunteers and in patients with chronic plaque psoriasis. Inventiva could receive milestone payments as well as royalties on future sales. For further information on the new clinical trial, please visit: https://clinicaltrials.gov/ct2/show/NCT03922607
Creation of a Scientific Advisory Board
Inventiva recently announced the creation of its Scientific Advisory Board (SAB) to provide scientific review and advice to the Company’s management with regards to its R&D activities and product portfolio. The SAB covers Inventiva’s key areas of research and development with a particular focus on NASH, MPS and oncology. The SAB also supports Inventiva’s management regarding the preclinical and clinical aspects of the Company’s development programs and its global scientific policy, including targets, fields of research, partnerships and market access.
Approval and implementation of a redundancy plan following the termination of the systemic sclerosis (“SSc”) program
Following the termination of the SSc program in February 2019 due to the failure to meet the primary endpoint of the FASST Phase IIb clinical study, the Company implemented a redundancy plan in the second quarter which was subject to a corporate agreement signed on June 11, 2019; combined with the non-renewal of fixed-term
PRESS RELEASE
contracts, the Company’s total workforce will be reduced from 118 to approximately 90 employees by the end of the year.
Key milestones expected
▪ Completion of patient recruitment in the NATIVE Phase IIb clinical study evaluating lanifibranor for the treatment of NASH
▪ Completion of patient recruitment in the Phase II clinical study evaluating lanifibranor for the treatment of NAFLD in patients with type 2 diabetes
▪ Launch of a new biomarker study in patients with MPS VI
▪ Results of the iMProveS Phase IIa clinical study
▪ Selection of the clinical candidate for the YAP-TEAD oncology program
Upcoming investor conferences
▪ Portzamparc Biotech Conference, Paris, September 10, 2019
▪ SFAF Meeting, Paris, September 17, 2019
▪ Forum Lyon Pôle Bourse, Lyon, September 25, 2019
▪ KBC Biotech Conference, Brussels, September 27, 2019
▪ Large & MidCap Event, Paris, October 14-15, 2019
▪ HC Wainwright NASH Conference, New York, October 21, 2019
▪ Gilbert Dupont NASH Day, Paris, October 29, 2019
▪ KOL and investors’ meeting at the American Association for the Study of Liver Diseases (AASLD) conference, Boston, November 9, 2019
▪ Jefferies 2019 London Healthcare Conference, London, November 20-21, 2019
Next financial results publication
▪ H1 2019 financial results: Thursday, September 26, 2019 (after market close)
Contacts
Inventiva
Frédéric Cren
Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00
Brunswick
Aude Hillion/ Yannick Tetzlaff
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83
LifeSci Advisors
Monique Kosse
Investor relations
monique@lifesciadvisors.com
Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.
Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.
Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.[/lvca_panel][lvca_panel panel_id=”panel-5bc0ba5831260″ panel_title=”Important Notice”]This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.
There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.
Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.[/lvca_panel][/lvca_accordion]
